Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs OneSpan Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while OneSpan Inc trades at $16.25 (market cap $603.27M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 15.6× OneSpan Inc's market cap, and OneSpan Inc pays a 3.18% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OSPN | |
|---|---|---|
Market Cap | $9.39B | $603.27M |
Sector | Health | Technology |
52-Week High | $356.25 | $16.78 |
52-Week Low | $241.71 | $10.15 |
Enterprise Value | $9.14B | $572.35M |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
OneSpan (OSPN) trades at $16.78, up 3.33% today, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a P/E of 9.25, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 revenue growth and raised full-year guidance, reflecting positive business momentum.
The outlook is positive, driven by earnings strength and strategic initiatives, but risks include competitive pressures and potential margin compression. With a consensus price target of $17.00 and 67% buy ratings, Wall Street sees modest upside from current levels amid overall solid financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
